Tenaya Therapeutics (TNYA) News Today $1.97 -0.05 (-2.48%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period What is Leerink Partnrs' Forecast for TNYA FY2024 Earnings?November 13, 2024 | americanbankingnews.comHC Wainwright Has Positive Estimate for TNYA FY2024 EarningsNovember 12, 2024 | americanbankingnews.comWhat is William Blair's Forecast for TNYA FY2024 Earnings?November 12, 2024 | americanbankingnews.comWhat is Lifesci Capital's Estimate for TNYA FY2024 Earnings?November 11, 2024 | americanbankingnews.comHC Wainwright Has Bullish Forecast for TNYA FY2024 EarningsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per shareNovember 11, 2024 | marketbeat.comLeerink Partnrs Has Bullish Outlook for TNYA FY2024 EarningsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2024 EPS estimates for Tenaya Therapeutics in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1November 11, 2024 | marketbeat.comWhat is Lifesci Capital's Forecast for TNYA FY2024 Earnings?Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Stock analysts at Lifesci Capital upped their FY2024 earnings estimates for shares of Tenaya Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Lifesci Capital analyst C. Jubinville now forecasts thNovember 11, 2024 | marketbeat.comEquities Analysts Set Expectations for TNYA FY2024 EarningsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Equities research analysts at William Blair boosted their FY2024 EPS estimates for shares of Tenaya Therapeutics in a research note issued to investors on Wednesday, November 6th. William Blair analyst S. Corwin now forecasts that the companNovember 11, 2024 | marketbeat.comTenaya Therapeutics price target raised to $18 from $16 at CanaccordNovember 10, 2024 | markets.businessinsider.comPromising Developments and Strong Financials Drive Buy Rating for Tenaya TherapeuticsNovember 8, 2024 | markets.businessinsider.comPositive Outlook for Tenaya Therapeutics: Strong Clinical Progress and Financial Position Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tenaya Therapeutics Amid Positive DSMB Update and Strong Financial PositionNovember 7, 2024 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $18.00 at Chardan CapitalChardan Capital cut their price target on Tenaya Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Thursday.November 7, 2024 | marketbeat.comTenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 6, 2024 | globenewswire.com550,700 Shares in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Bought by abrdn plcabrdn plc acquired a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 550,700 shares of the company's stock, valued at approximately $1,063,000. abrdn plc owned 0.70% of Tenaya TheNovember 5, 2024 | marketbeat.comHere's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn SituationNovember 2, 2024 | uk.finance.yahoo.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by AnalystsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has received an average rating of "Buy" from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12 month target price among bOctober 30, 2024 | marketbeat.comTD Cowen Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)October 22, 2024 | markets.businessinsider.comOptimistic Outlook for Tenaya Therapeutics Amid Positive Trial Developments for TN-201October 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Sana Biotechnology (SANA)October 19, 2024 | markets.businessinsider.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCMOctober 18, 2024 | finanznachrichten.dePromising Developments and DSMB Approval Drive Buy Rating for Tenaya TherapeuticsOctober 18, 2024 | markets.businessinsider.comTenaya Therapeutics (TNYA) Receives a Buy from Piper SandlerOctober 18, 2024 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Rating Reiterated by Canaccord Genuity GroupCanaccord Genuity Group reaffirmed a "buy" rating and set a $16.00 price target on shares of Tenaya Therapeutics in a research report on Friday.October 18, 2024 | marketbeat.comTenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCMOctober 17, 2024 | globenewswire.comTenaya Therapeutics (NASDAQ:TNYA) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTenaya Therapeutics (NASDAQ:TNYA) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by BrokeragesShares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have received a consensus rating of "Buy" from the six ratings firms that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price objectiveOctober 5, 2024 | marketbeat.comOptimistic Buy Rating for Tenaya Therapeutics as Clinical Milestone Nears in Gene Therapy for CardiomyopathyOctober 2, 2024 | markets.businessinsider.comBuy Rating Reiterated on Tenaya Therapeutics Amid Promising Gene Therapy Prospects for HCMSeptember 24, 2024 | markets.businessinsider.comOwning 43% shares,institutional owners seem interested in Tenaya Therapeutics, Inc. (NASDAQ:TNYA),September 21, 2024 | finance.yahoo.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Buy" from AnalystsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has earned a consensus rating of "Buy" from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target priceSeptember 10, 2024 | marketbeat.comTenaya Therapeutics to Participate in Upcoming Investment ConferencesSeptember 3, 2024 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Insider Whittemore Tingley Sells 7,428 SharesAugust 17, 2024 | insidertrades.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Buy" from BrokeragesTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been given a consensus recommendation of "Buy" by the six research firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year targAugust 16, 2024 | marketbeat.comVanguard Group Inc. Increases Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Vanguard Group Inc. boosted its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 16.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,862,916 shares of the company's stock afteAugust 13, 2024 | marketbeat.comBuy Rating on Tenaya Therapeutics: Promising Clinical Trials and Solid Financial PositionAugust 10, 2024 | markets.businessinsider.comTNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q2 2024August 9, 2024 | investorplace.comPrice T Rowe Associates Inc. MD Sells 1,198,021 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Price T Rowe Associates Inc. MD reduced its holdings in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 26.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,346,522 shares of the cAugust 3, 2024 | marketbeat.com5 Penny Stocks With 250% Upside in 1 Year According to Wall StreetJuly 30, 2024 | 247wallst.comAnalysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)July 26, 2024 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Monday.July 8, 2024 | marketbeat.comTenaya Therapeutics Announces Research Leadership UpdatesJune 27, 2024 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Buy" from BrokeragesTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average 12 month price objective amoJune 27, 2024 | marketbeat.comTenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA SummitJune 18, 2024 | globenewswire.comChardan Capital Comments on Tenaya Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TNYA)Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Investment analysts at Chardan Capital dropped their FY2024 earnings estimates for shares of Tenaya Therapeutics in a report released on Tuesday, May 28th. Chardan Capital analyst Y. Livshits now anticipates that the company will earn ($1.61May 31, 2024 | marketbeat.comWe're Keeping An Eye On Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn RateMay 25, 2024 | finance.yahoo.comCanaccord Genuity Group Trims Tenaya Therapeutics (NASDAQ:TNYA) Target Price to $16.00Canaccord Genuity Group lowered their price objective on shares of Tenaya Therapeutics from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Thursday.May 16, 2024 | marketbeat.comBuy Rating Affirmed for Tenaya Therapeutics on Strong Program Prospects and Financial StabilityMay 16, 2024 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research note on Wednesday.May 15, 2024 | marketbeat.com Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov TNYA Media Mentions By Week TNYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNYA News Sentiment▼0.870.55▲Average Medical News Sentiment TNYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNYA Articles This Week▼222▲TNYA Articles Average Week Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Adaptimmune Therapeutics News Today Precigen News Today BioAtla News Today uniQure News Today LianBio News Today 4D Molecular Therapeutics News Today Absci News Today Dianthus Therapeutics News Today Evolus News Today Tyra Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNYA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
